Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

600196 · SSE

Public Market Listing

600196SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(10 total)
10Total Assets
2Approved
3Phase 3 / Filed
5Phase 1–2 / Early
10Diseases
Quick filter:
Showing 10 of 10 assets
Target & Modality
Approved
Iron-replacement therapy delivered via dialysateSmall molecule
Chronic Kidney DiseaseIron Deficiency Anemia
Approved
NHE3 (sodium/hydrogen exchanger isoform 3)Small molecule
Chronic Kidney DiseaseHyperphosphatemia
Phase 3
ALK / ROS1Small molecule
Non-Small Cell Lung Cancer
Phase 3
MEK1/2Small molecule
Non-Small Cell Lung CancerGlioma
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung CancerSmall Cell Lung CancerGastric Cancer
Phase 2
TYK2Small molecule
Psoriasis
bremelanotide(Vyleesi)
Phase 2
MC4RPeptide
Obesity
Phase 2
BCL-2Small molecule
Acute Myeloid Leukemia
Phase 1
BCL-2Small molecule
Acute Myeloid Leukemia
Phase 1
IRAK4 / BTKSmall molecule
Acute Myeloid Leukemia

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
FCN-338Phase 2Safety, Antitumor Activity, PK Profile
Est. primary completion 2026-12-01 · NCT06858618 · CT.gov ↗
What to watch
2027 (5)
April 2027 (1)
LuvometinibPhase 3Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration
Est. primary completion 2027-04-30 · NCT07004075 · CT.gov ↗
What to watch
May 2027 (1)
SerplulimabPhase 2Breast Cancer (Triple Negative Breast Cancer (TNBC))
Est. primary completion 2027-05-15 · NCT07487519 · CT.gov ↗
What to watch
June 2027 (1)
SerplulimabPhase 2Non Small Cell Lung Cancer, Small Cell Lung Cancer
Est. primary completion 2027-06-18 · NCT07253142 · CT.gov ↗
What to watch
July 2027 (1)
SerplulimabPhase 1/2Colon Cancer Adenocarcinoma
Est. primary completion 2027-07-28 · NCT07358585 · CT.gov ↗
What to watch
December 2027 (1)
SerplulimabPhase 2Carcinoma of Head and/or Neck
Est. primary completion 2027-12-30 · NCT06857279 · CT.gov ↗
What to watch
2029 (2)
June 2029 (1)
LuvometinibPhase 2Non-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous Treamted
Est. primary completion 2029-06 · NCT07562581 · CT.gov ↗
What to watch
September 2029 (1)
LuvometinibPhase 1/2Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Est. primary completion 2029-09-23 · NCT07024394 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
SerplulimabPhase 2/3Squamous NSCLC
Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

January 2026Filing acceptedForitinib succinateNMPA accepts foritinib succinate capsules NDA (January 2026)
CN, NMPA · Fosun Pharma · Source ↗
20 May 2025Topline resultAC-201Phase 2 (NCT06972888) of AC-201 in moderate-to-severe plaque psoriasis met its primary endpoint (PASI-75 at week 12) at all three doses
Accropeutics · Source ↗
31 March 2025Topline resultbremelanotideBMT-801 Phase 2 obesity co-administration study meets primary endpoint
10 March 2025Filing acceptedForitinib succinateNMPA accepts foritinib marketing authorization application
CN, NMPA · Fosun Pharma · Source ↗
Q1 2025Topline resultbremelanotidePhase 2 of bremelanotide with tirzepatide met its primary endpoint

Financial reports

No financial reports recorded.